8-K: Arrowhead Reports Q3 2025 Results, Advances Pipeline

Arrowhead Pharmaceuticals announced its fiscal 2025 third-quarter results, highlighting significant progress in its clinical pipeline, strategic partnerships, and a strong balance sheet.

Summary

• Reported fiscal 2025 third-quarter results for the period ended June 30, 2025.
• Secured a $130 million upfront payment from Sanofi for an exclusive license to develop and commercialize plozasiran in Greater China, with potential for up to $265 million in additional milestone payments.
• Received a $100 million milestone payment from Sarepta Therapeutics for ARO-DM1, with an additional $200 million expected by the end of 2025.
• Completed enrollment in three global Phase 3 clinical studies (SHASTA-3, SHASTA-4, and MUIR-3) for plozasiran in severe hypertriglyceridemia, with topline data expected mid-2026.
• The U.S. FDA has accepted the New Drug Application (NDA) for plozasiran in familial chylomicronemia syndrome (FCS) with a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025.
• Initiated the Phase 3 YOSEMITE clinical trial for zodasiran in homozygous familial hypercholesterolemia (HoFH).
• Commenced a Phase 1/2a clinical trial for ARO-ALK7 for obesity, with plans to investigate combinations with tirzepatide.
• Reported revenue of $27.8 million for the quarter, compared to $0 in the prior year.
• Net loss attributable to Arrowhead Pharmaceuticals, Inc. increased to $175.2 million from $170.8 million year-over-year.
• Total cash resources increased to $900.4 million as of June 30, 2025, from $681.0 million as of September 30, 2024.

Sentiment

Score: 8

Explanation: The company demonstrated strong operational execution with multiple pipeline advancements, significant milestone achievements, and a strengthened balance sheet. The upcoming PDUFA date for plozasiran and expected future milestone payments provide clear positive catalysts. While net loss increased, it is typical for a company in late-stage clinical development, and the improved cash position mitigates concerns.

Positives

• Secured a $130 million upfront payment from Sanofi for plozasiran rights in Greater China, with potential for an additional $265 million in milestone payments.
• Received a $100 million milestone payment from Sarepta Therapeutics for ARO-DM1, with another $200 million expected by year-end 2025.
• Completed enrollment in three pivotal Phase 3 studies for plozasiran (SHASTA-3, SHASTA-4, MUIR-3), indicating significant progress towards regulatory submissions.
• Plozasiran NDA for familial chylomicronemia syndrome (FCS) accepted by the U.S. FDA with a PDUFA date of November 18, 2025, signaling potential near-term market approval.
• Initiated Phase 3 YOSEMITE clinical trial for zodasiran, marking the fourth RNAi candidate in late-stage pivotal studies.
• Commenced Phase 1/2a clinical trial for ARO-ALK7 for obesity, expanding the pipeline into a high-demand therapeutic area with a novel mechanism.
• Revenue for the quarter was $27.8 million, a significant increase from $0 in the prior year, driven by collaboration agreements.
• Operating loss improved to $(165.5) million from $(176.1) million year-over-year.
• Total cash resources increased by $219.4 million to $900.4 million, strengthening the balance sheet.
• Total liabilities decreased by $87.9 million to $860.8 million.
• Stockholders' equity significantly increased by $336.9 million to $522.3 million.

Negatives

• Net loss attributable to Arrowhead Pharmaceuticals, Inc. increased to $175.2 million for the quarter, compared to $170.8 million in the prior year.
• Total other (expense) income shifted from an income of $2.2 million in the prior year to an expense of $13.5 million.
• Research and development expenses increased by $9.9 million to $162.4 million, reflecting higher clinical trial costs.
• General and administrative expenses increased by $7.2 million to $30.9 million, likely due to commercial buildout and operational expansion.

Risks

• Impact of the ongoing COVID-19 pandemic on business operations.
• Uncertainty regarding the safety and efficacy of product candidates.
• Reliance on decisions of regulatory authorities and the timing of approvals.
• Potential for duration and impact of regulatory delays in clinical programs.
• Ability to finance operations and secure future funding.
• Uncertainty regarding the likelihood and timing of the receipt of future milestone and licensing fees.
• Risks associated with the future success of scientific studies.
• Challenges in successfully developing and commercializing drug candidates.
• Uncertainty regarding the timing for starting and completing clinical trials.
• Risk of rapid technological change in the markets.
• Challenges in the enforcement of intellectual property rights.

Future Outlook

The company anticipates completing the primary portion of plozasiran's Phase 3 studies in severe hypertriglyceridemia by mid-2026, with topline data expected shortly thereafter and planned regulatory submissions to follow. An additional $200 million milestone payment from Sarepta Therapeutics is expected by the end of 2025 upon achieving the second enrollment target for ARO-DM1. The U.S. FDA has set a PDUFA action date of November 18, 2025, for plozasiran in familial chylomicronemia syndrome, indicating a potential near-term market approval.

Management Comments

• We continue to achieve strong execution in discovery, clinical and regulatory, and business development.
• Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies.
• Our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025, PDUFA date.
• We continue to maintain a strong balance sheet, which we believe gives us the financial resources to move multiple innovative new medicines through the clinical and regulatory process and ultimately get them to the patients who need them.

Industry Context

Arrowhead Pharmaceuticals operates in the highly competitive RNA interference (RNAi) therapeutic space, a rapidly advancing field for treating genetic and intractable diseases. The company's progress with multiple candidates in pivotal Phase 3 studies, including plozasiran, zodasiran, and fazirsiran (licensed to Takeda), positions it among leaders in RNAi drug development alongside companies like Alnylam Pharmaceuticals and Dicerna Pharmaceuticals (acquired by Novo Nordisk). The expansion into cardiometabolic diseases (hypertriglyceridemia, HoFH) and obesity with ARO-ALK7 aligns with major unmet medical needs and large market opportunities, attracting significant pharmaceutical interest and investment, as evidenced by the Sanofi and Sarepta collaborations. The PDUFA date for plozasiran highlights the increasing maturity of RNAi therapies moving towards commercialization.

Comparison to Industry Standards

• The company's pipeline maturity, with four RNAi candidates in pivotal Phase 3 studies (plozasiran, zodasiran, fazirsiran, olpasiran), is comparable to leading RNAi developers like Alnylam Pharmaceuticals, which has multiple approved and late-stage RNAi drugs.
• The upfront payment of $130 million from Sanofi for Greater China rights to plozasiran, with potential milestones up to $265 million, reflects a strong valuation for late-stage cardiometabolic assets in key emerging markets, similar to licensing deals seen with other innovative therapies.
• The $100 million milestone from Sarepta Therapeutics for ARO-DM1, with a further $200 million expected, demonstrates the significant value placed on rare disease assets and the progress of RNAi in neuromuscular disorders, comparable to the high-value partnerships seen in the gene therapy and rare disease sectors.
• The initiation of a Phase 1/2a trial for ARO-ALK7 in obesity, with a novel mechanism targeting fat storage and potential for lean muscle preservation, positions Arrowhead in a competitive landscape with companies developing GLP-1 agonists (e.g., Eli Lilly's Zepbound/tirzepatide, Novo Nordisk's Wegovy/semaglutide), but with a differentiated approach.

Stakeholder Impact

• Shareholders: Positive impact due to significant pipeline progress, substantial milestone payments, strengthened balance sheet, and potential near-term regulatory approval for plozasiran, which could drive share price appreciation.
• Patients: Positive impact with multiple investigational RNAi therapeutics advancing towards potential market approval for severe hypertriglyceridemia, familial chylomicronemia syndrome, homozygous familial hypercholesterolemia, type 1 myotonic dystrophy, and obesity, addressing significant unmet medical needs.
• Employees: Continued stability and growth opportunities as the company expands its clinical programs and prepares for potential commercialization.
• Partners (Sanofi, Sarepta, Takeda, Amgen): Continued collaboration and potential for further milestone payments and successful product development.
• Creditors: Improved financial position with increased cash resources and decreased credit facility obligations, enhancing creditworthiness.

Next Steps

• Conference call and webcast on August 7, 2025, at 4:30 p.m. ET to discuss results.
• Anticipated achievement of the second enrollment target for ARO-DM1 by the end of 2025, triggering a $200 million milestone payment from Sarepta.
• U.S. FDA PDUFA action date for plozasiran in familial chylomicronemia syndrome (FCS) on November 18, 2025.
• Completion of the primary portion of plozasiran SHASTA-3, SHASTA-4, and MUIR-3 studies in mid-2026.
• Topline data for plozasiran SHASTA-3, SHASTA-4, and MUIR-3 studies expected shortly after mid-2026.
• Planned regulatory submissions for plozasiran in severe hypertriglyceridemia to follow topline data.
• Progression of ARO-ALK7 Phase 1/2a study to investigate combinations with tirzepatide in obese patients.

Key Dates

Recommendation

The filing demonstrates exceptional operational execution and significant strategic advancements. The company secured substantial non-dilutive funding through milestone payments ($100M received, $200M expected) and a licensing deal ($130M upfront, $265M potential milestones). Plozasiran is on track for a PDUFA decision in November 2025, representing a near-term commercialization catalyst. The pipeline is robust with four candidates in Phase 3, and a new obesity program (ARO-ALK7) has entered clinical trials, targeting a massive market. Financially, the balance sheet is strong with over $900 million in cash resources and reduced liabilities, providing ample runway for continued development. Despite an increased net loss, this is expected for a company with an expanding late-stage pipeline. The combination of clinical progress, strategic partnerships, and financial strength makes Arrowhead Pharmaceuticals a compelling investment.

Keywords

RNAi, Arrowhead Pharmaceuticals, ARWR, Plozasiran, Zodasiran, ARO-ALK7, ARO-DM1, Hypertriglyceridemia, Familial Chylomicronemia Syndrome, Homozygous Familial Hypercholesterolemia, Obesity, Type 1 Myotonic Dystrophy, Clinical Trials, Phase 3, Drug Development, Biotechnology, Pharmaceuticals, SEC Filing, Financial Results, Milestone Payments, Sanofi, Sarepta Therapeutics, FDA PDUFA